Sai Parenteral’s IPO Day 2: Global Ambitions vs. Premium Pricing—A Strategic Pharma Play?
Hyderabad-based Sai Parenteral's enters Day 2 of its ₹409 crore IPO with a price band of ₹372–₹392. While Day 1 saw a muted 0.05x subscription and a flat ₹0 GMP, the company’s recent Australian acquisition and strong anchor book (including Morgan Stanley) suggest a long-term story. We break down the financials and the "Noumed" factor.
Live IPO Tracking Available
Check live GMP, allotment status, and deep analysis for this IPO.
1. Live Status: Day 2 Update (March 25)
The bidding process is currently underway. After the first day of subscription, here is the current pulse:
Total Subscription: The issue was subscribed 0.05x (5%) at the end of Day 1.
Segment Breakdown: Retail was at 0.03x, while Non-Institutional Investors (NII) stood at 0.15x. Qualified Institutional Buyers (QIBs) typically wait until the final day
Grey Market (GMP): Currently trading at ₹0. This indicates the market expects a flat listing at ₹392, with no immediate "quick buck" gains expected.
2. The "Noumed" Catalyst: Why the Big Funds are Watching
Despite the slow retail start, the company's business model is shifting gears:
Australian Beachhead: Through its Singapore subsidiary, Sai Parenteral's has acquired a controlling stake in Noumed Pharmaceuticals (Australia). This gives them immediate access to 451 TGA-approved product dossiers.
High-Margin Injectables: The company is doubling down on complex injectables, which offer much better margins than standard tablets.
Blue-Chip Anchors: Before opening to the public, they raised ₹122.6 crore from top-tier names like Morgan Stanley Asia and Kotak Mahindra Life Insurance, showing strong institutional backing.
3. IPO Snapshot & Timeline
| Event / Detail | Important Dates & Info |
|---|---|
| IPO Closing Date | Friday, March 27, 2026 |
| Price Band | ₹372 to ₹392 per share |
| Lot Size | 38 Shares |
| Retail Min. Investment | ₹14,896 (1 Lot) |
| Allotment Date | Monday, March 30, 2026 |
| Listing Date | Thursday, April 2, 2026 (NSE & BSE) |
4. Financials: Growth at a Premium
The company’s trajectory is upward, but it comes with a high price tag for new investors:
Revenue: Jumped from ₹97 crore (FY23) to ₹163.74 crore (FY25).
Profit (PAT): Rose from ₹4.38 crore to ₹14.43 crore in the same period.
Valuation: At the upper price band, the P/E ratio is ~72x. This is significantly higher than peers like Gland Pharma (~44x) or Innova Captab (~32x). You are essentially paying for 2–3 years of future growth today.
5. The Verdict: Subscribe or Avoid?
The Bull Case (The "Pros"):
Strategic Acquisition: Buying Noumed leapfrogs years of regulatory hurdles in Australia and New Zealand.
Injectable Focus: Their focus on sterile manufacturing for critical care is a high-entry-barrier niche.
Fresh Capital: ₹111 crore of the proceeds will go directly into expanding manufacturing capacity.
The Bear Case (The "Cons"):
Expensive Valuation: The 72x P/E leaves very little margin for error if the Australian integration faces delays.
Low ROCE: A Return on Capital Employed of 9.28% is currently lower than industry leaders, though expected to improve post-expansion.
Muted Sentiment: The zero GMP suggests that listing gains are unlikely; this is purely a "buy and hold" candidate.